This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
This rating reflects Lupin's leadership in environmental transparency and performance
Plans underway to expand screening capacity by 50% for greater accessibility
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Q3 FY25 revenue up 24% to Rs 3,230 crore
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
Subscribe To Our Newsletter & Stay Updated